Literature DB >> 16433628

Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34+ cell recovery.

Claudia Del Fante1, Cesare Perotti, Gianluca Viarengo, Paola Bergamaschi, Carmine Tinelli, Laura Bellotti, Andrea Marchesi, Cristina Parisi, Laura Salvaneschi.   

Abstract

Immunomagnetic CD34+ cell selection (ICS) is a widely employed technology in autotransplant and allotransplant settings. When an haploidentical transplant is performed, a high dose of purified CD34+ cells together with efficient T and B cell depletion are required to minimize the risks of graft versus host disease (GVHD) and Epstein-Barr virus (EBV)-related lymphoma. To ameliorate the performances of the CliniMACS (Miltenyi Biotec) ICS device, we compared 73 ICS performed following the manufacturer's recommended platelet depletion versus 48 performed after adjunctive centrifugations to increase platelet depletion of the leukapheresis (LKF) product. A total of 121 ICS (from single or fractioned LKF products) were carried out on 93 LKF collected from 47 related healthy donors. A statistical significance in terms of CD34+ cell recovery (81.8% vs. 71.2%) was found in favor of the modified ICS procedure (p=0.0049) with a comparable stem cell purity and viability. The modification of the standard manufacturer's technique for increasing platelet depletion can further improve the recovery of stem cells with no influence on T and B cell depletion. These results demonstrate the negative influence exerted on CD34+ cell recovery by LKF platelet contamination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16433628     DOI: 10.1089/scd.2005.14.734

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  3 in total

1.  Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.

Authors:  Carolyn A Keever-Taylor; Steven M Devine; Robert J Soiffer; Adam Mendizabal; Shelly Carter; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Steven C Goldstein; Edward A Stadtmauer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-26       Impact factor: 5.742

2.  Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates.

Authors:  David F Stroncek; Minh Tran; Sue Ellen Frodigh; Virginia David-Ocampo; Jiaqiang Ren; Andre Larochelle; Virginia Sheikh; Irini Sereti; Jeffery L Miller; Kevin Longin; Marianna Sabatino
Journal:  Transfusion       Date:  2015-10-27       Impact factor: 3.157

3.  Efficient removal of platelets from peripheral blood progenitor cell products using a novel micro-chip based acoustophoretic platform.

Authors:  Josefina Dykes; Andreas Lenshof; Ing-Britt Åstrand-Grundström; Thomas Laurell; Stefan Scheding
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.